Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial

AIMS: In the EMPA‐REG OUTCOME trial, empagliflozin reduced risk of death from heart failure (HF) or hospitalization for heart failure (HHF) versus placebo in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease. We evaluated post hoc the degree to which covariate...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitchett, David, Inzucchi, Silvio E., Zinman, Bernard, Wanner, Christoph, Schumacher, Martin, Schmoor, Claudia, Ohneberg, Kristin, Ofstad, Anne Pernille, Salsali, Afshin, George, Jyothis T., Hantel, Stefan, Bluhmki, Erich, Lachin, John M., Zannad, Faiez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712833/
https://www.ncbi.nlm.nih.gov/pubmed/34605192
http://dx.doi.org/10.1002/ehf2.13615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712833/
https://www.ncbi.nlm.nih.gov/pubmed/34605192
http://dx.doi.org/10.1002/ehf2.13615

Ejemplares similares